

# CANADIAN PATENT GRANTED FOR BARD1 TECHNOLOGY

- Canadian Patent No. 2,929,457 granted covering lung cancer diagnosis
- IP protection in Canada for BARD1 autoantibody test for diagnosis of lung cancer in Canada

**Melbourne, Australia, 27 October 2022:** INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) announces that Canadian Patent 2,929,457 titled 'Lung Cancer Diagnosis' was issued by the Canadian Intellectual Property Office.

The patent claims are directed towards methods for detecting antibodies to BARD1 peptides, methods for diagnosing lung cancer and kits for lung cancer diagnosis. The patent application was filed by BARD1AG SA (a fully owned subsidiary of INOVIQ Ltd) on 5 November 2014 and is due to expire on 5 November 2034.

*Authorised by the Company Secretary, Tony Di Pietro.*

- ENDS -

## COMPANY CONTACTS

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman  
E [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M +61 417 203 021

**Jane Lowe**  
IR Department  
E [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M +61 411 117 774

## ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see [www.inoviq.com](http://www.inoviq.com).

## FORWARDING LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.